4 transcripts
TECH
Earnings call transcript
NASDAQ
2024 Q4
7 Aug 24
funding environment for biotech and a significant R&D budget recalibration by large pharma and academia customers. Let me give you some examples
TECH
Earnings call transcript
NASDAQ
2024 Q3
1 May 24
of the Lunaphore acquisition in this fiscal year.
Adjusted SG&A in Q3 was 30.3% of revenue compared to 27.9% in the prior year, while R&D expense in Q3
TECH
Earnings call transcript
NASDAQ
2024 Q2
1 Feb 24
mix and the impact of the Lunaphore acquisition. Adjusted SG&A in Q2 was 31.2% of revenue compared to 27.9% in the prior year while R&D expense in Q2
TECH
Earnings call transcript
NASDAQ
2023 Q4
8 Aug 23
with our R&D Systems brand of reagents. This unique offering and our reputation as the highest quality producer drove Q4 growth to almost 60% and our
- Prev
- 1
- Next